Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | DORA trial: radium-223 plus docetaxel for mCRPC

Michael Morris • 15 Feb 2019
GU Cancers 2019
Genitourinary Cancer Prostate Cancer Docetaxel Radium-223
DORA

Michael Morris, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the aims, rationale and implications of the DORA trial (NCT03574571), which investigated the effect of radium-223 with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Michael Morris

5:42
Atezolizumab with radium-223 in metastatic castrate-resistant prostate cancer
Michael Morris • 22 May 2020
7:42
CONDOR: 18F-DCFPyL PET/CT imaging in suspected reccuring prostate cancer
Michael Morris • 22 May 2020
1:42
Role of Medical Oncologists in prostate cancer management
Michael Morris • 15 Feb 2019
1:01
A promising treatment for prostate cancer
Michael Morris • 15 Feb 2019

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals